| Cod Nacion | Nro Definitivo | Des Nomco | Des Prese | Cod Vtm | Cod Vmp | Cod Vmpp | Des Dosific | Cod Forfar | Cod Forfar Simplificada | Cod Envase | Contenido | Unid Contenido | Nro Conte | Cod Atc | Sw Psicotropo | Sw Estupefaciente | Sw Afecta Conduccion | Sw Triangulo Negro | Url Fictec | Url Prosp | Sw Receta | Sw Generico | Sw Sustituible | Sw Envase Clinico | Sw Uso Hospitalario | Sw Diagnostico Hospitalario | Sw Tld | Sw Especial Control Medico | Sw Huerfano | Sw Base A Plantas | Laboratorio Titular | Laboratorio Comercializador | Fecha Autorizacion | Sw Comercializado | Cod Sitreg | Cod Sitreg Presen | Fecha Situacion Registro | Fec Sitreg Presen | Sw Tiene Excipientes Decl Obligatoria | Nro Pactiv | Fec Comer | Lista Psicotropo | Cod Nacionales Inactivos | Lista Estupefaciente | Hash | Last Modified | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 732023 | 1201446001 | HEPCLUDEX 2 MG POLVO PARA SOLUCION INYECTABLE | HEPCLUDEX 2 MG POLVO PARA SOLUCION INYECTABLE, 30 viales | 2 mg | 45 | 30 | 34 | 30 viales | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201446001/1201446001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201446001/1201446001_p.pdf | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 16632 | GILEAD SCIENCES S.L. | 2021-10-26 | 1 | 1 | 1 | 2021-10-27 | 2021-10-26 | 1 | 2024-01-15 | View Edit Delete | ||||||||||||
| 729297 | 1201448001 | CABAZITAXEL ACCORD 20 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION | CABAZITAXEL ACCORD 20 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 3 ml | 60 mg inyectable 3 ml | 45 | 1 | 34 | 1 vial de 3 ml | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201448001/1201448001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201448001/1201448001_p.pdf | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2020-10-20 | 1 | 1 | 1 | 2020-10-21 | 2020-10-20 | 1 | 2021-04-12 | View Edit Delete | ||||||||||||
| 731004 | 1201450005 | FINGOLIMOD ACCORD 0,5 mg CAPSULAS DURAS EFG | FINGOLIMOD ACCORD 0,5 mg CAPSULAS DURAS EFG, 28 cápsulas | 0,5 mg | 5 | 28 | 43 | 28 cápsulas | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201450005/1201450005_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201450005/1201450005_p.pdf | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2021-06-07 | 1 | 1 | 1 | 2021-06-08 | 2021-06-07 | 1 | 2023-04-11 | View Edit Delete | ||||||||||||
| 728878 | 1201452001 | REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE | REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE, 1 vial | 25 mg | 45 | 1 | 34 | 1 vial | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201452001/1201452001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201452001/1201452001_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 31892 | BRISTOL MYERS SQUIBB S.A. | 2020-08-18 | 1 | 1 | 1 | 2020-08-20 | 2020-08-18 | 1 | 2023-08-03 | View Edit Delete | ||||||||||||
| 728879 | 1201452002 | REBLOZYL 75 MG POLVO PARA SOLUCION INYECTABLE | REBLOZYL 75 MG POLVO PARA SOLUCION INYECTABLE, 1 vial | 75 mg | 45 | 1 | 34 | 1 vial | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201452002/1201452002_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201452002/1201452002_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 31892 | BRISTOL MYERS SQUIBB S.A. | 2020-08-18 | 1 | 1 | 1 | 2020-08-20 | 2020-08-18 | 1 | 2023-08-03 | View Edit Delete | ||||||||||||
| 732561 | 1201453007 | BYANNLI 700 MG SUSPENSION INYECTABLE DE LIBERACION PROLONGADA EN JERINGA PRECARGADA | BYANNLI 700 MG SUSPENSION INYECTABLE DE LIBERACION PROLONGADA EN JERINGA PRECARGADA, 1 jeringa precargada + 1 aguja | 700 mg inyectable 3,5 ml | 33 | 1 | 61 | 1 jeringa precargada + 1 aguja | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201453007/1201453007_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201453007/1201453007_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6153 | JANSSEN CILAG S.A. | 2022-01-14 | 1 | 1 | 1 | 2022-01-15 | 2022-01-14 | 1 | 2022-03-14 | View Edit Delete | ||||||||||||
| 732562 | 1201453008 | BYANNLI 1.000 MG SUSPENSION INYECTABLE DE LIBERACION PROLONGADA EN JERINGA PRECARGADA | BYANNLI 1.000 MG SUSPENSION INYECTABLE DE LIBERACION PROLONGADA EN JERINGA PRECARGADA, 1 jeringa precargada + 1 aguja | 1.000 mg inyectable 5 ml | 33 | 1 | 61 | 1 jeringa precargada + 1 aguja | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201453008/1201453008_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201453008/1201453008_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6153 | JANSSEN CILAG S.A. | 2022-01-14 | 1 | 1 | 1 | 2022-01-15 | 2022-01-14 | 1 | 2022-03-14 | View Edit Delete | ||||||||||||
| 729169 | 1201454001 | AYBINTIO 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION | AYBINTIO 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 4 ml | 25 mg/ml inyectable 4 ml | 45 | 1 | 34 | 1 vial de 4 ml | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201454001/1201454001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201454001/1201454001_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 29985 | ORGANON SALUD S.L. | 2020-09-07 | 1 | 1 | 1 | 2020-09-08 | 2020-09-07 | 1 | 2020-10-20 | View Edit Delete | ||||||||||||
| 729170 | 1201454001 | AYBINTIO 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION | AYBINTIO 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 16 ml | 25 mg/ml inyectable 16 ml | 45 | 1 | 34 | 1 vial de 16 ml | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201454001/1201454001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201454001/1201454001_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 29985 | ORGANON SALUD S.L. | 2020-09-07 | 1 | 1 | 1 | 2020-09-08 | 2020-09-07 | 1 | 2020-10-20 | View Edit Delete | ||||||||||||
| 729116 | 1201455002 | PIQRAY 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA | PIQRAY 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 56 comprimidos | 150 mg | 5 | 56 | 10 | 56 comprimidos | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201455002/1201455002_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201455002/1201455002_p.pdf | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 28642 | NOVARTIS FARMACEUTICA S.A. | 2020-08-25 | 1 | 1 | 1 | 2020-08-26 | 2020-08-25 | 1 | 2021-11-11 | View Edit Delete | ||||||||||||
| 729126 | 1201455005 | PIQRAY 50 MG y 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULA | PIQRAY 50 MG y 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 56 comprimidos (28 x 50 mg + 28 x 200 mg) | 50 mg + 200 mg | 5 | 56 | 10 | 56 comprimidos (28 x 50 mg + 28 x 200 mg) | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201455005/1201455005_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201455005/1201455005_p.pdf | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 28642 | NOVARTIS FARMACEUTICA S.A. | 2020-08-25 | 1 | 1 | 1 | 2020-08-26 | 2020-08-25 | 1 | 2021-11-11 | View Edit Delete | ||||||||||||
| 729127 | 1201455008 | PIQRAY 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULA | PIQRAY 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidos | 200 mg | 5 | 28 | 10 | 28 comprimidos | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201455008/1201455008_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201455008/1201455008_p.pdf | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 28642 | NOVARTIS FARMACEUTICA S.A. | 2020-08-25 | 1 | 1 | 1 | 2020-08-26 | 2020-08-25 | 1 | 2021-11-11 | View Edit Delete | ||||||||||||
| 728786 | 1201456001 | ZERCEPAC 150 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION | ZERCEPAC 150 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial | 150 mg | 45 | 1 | 34 | 1 vial | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201456001/1201456001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201456001/1201456001_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2020-08-03 | 1 | 1 | 1 | 2020-08-04 | 2020-08-03 | 1 | 2020-10-13 | View Edit Delete | ||||||||||||
| 730810 | 1201456002 | ZERCEPAC 60 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION | ZERCEPAC 60 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial | 60 mg | 45 | 1 | 34 | 1 vial | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201456002/1201456002_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201456002/1201456002_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2021-05-28 | 1 | 1 | 1 | 2021-05-29 | 2021-05-28 | 1 | 2021-08-05 | View Edit Delete | ||||||||||||
| 731333 | 1201456003 | ZERCEPAC 420 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION | ZERCEPAC 420 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial | 420 mg | 45 | 1 | 34 | 1 vial | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201456003/1201456003_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201456003/1201456003_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2021-07-29 | 1 | 1 | 1 | 2021-07-30 | 2021-07-29 | 1 | 2021-10-13 | View Edit Delete | ||||||||||||
| 728902 | 1201459002 | VEKLURY 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION | VEKLURY 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial | 100 mg | 45 | 1 | 34 | 1 vial | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201459002/1201459002_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201459002/1201459002_p.pdf | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 16632 | GILEAD SCIENCES S.L. | 2020-07-13 | 1 | 1 | 1 | 2020-07-14 | 2020-07-13 | 1 | 2021-02-12 | View Edit Delete | ||||||||||||
| 729114 | 1201460001 | ROZLYTREK 100 MG CAPSULAS DURAS | ROZLYTREK 100 MG CAPSULAS DURAS, 30 cápsulas | 100 mg | 6 | 30 | 43 | 30 cápsulas | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201460001/1201460001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201460001/1201460001_p.pdf | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 29096 | ROCHE FARMA S.A. | 2020-08-27 | 1 | 1 | 1 | 2020-08-28 | 2020-08-27 | 1 | 2023-11-13 | View Edit Delete | ||||||||||||
| 729115 | 1201460002 | ROZLYTREK 200 MG CAPSULAS DURAS | ROZLYTREK 200 MG CAPSULAS DURAS, 90 cápsulas | 200 mg | 6 | 90 | 43 | 90 cápsulas | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201460002/1201460002_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201460002/1201460002_p.pdf | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 29096 | ROCHE FARMA S.A. | 2020-08-27 | 1 | 1 | 1 | 2020-08-28 | 2020-08-27 | 1 | 2023-11-13 | View Edit Delete | ||||||||||||
| 765587 | 1201460003 | ROZLYTREK 50 MG GRANULADO RECUBIERTO CON PELICULA EN SOBRE | ROZLYTREK 50 MG GRANULADO RECUBIERTO CON PELICULA EN SOBRE, 42 sobres | 50 mg | 35 | 42 | 64 | 42 sobres | 0 | 0 | 0 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1201460003/1201460003_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201460003/1201460003_p.pdf | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 29096 | ROCHE FARMA S.A. | 2024-08-16 | 1 | 1 | 1 | 2024-08-17 | 2024-08-16 | 1 | 2026-05-05 | View Edit Delete | ||||||||||||
| 729237 | 1201462001 | LIVOGIVA 20 MICROGRAMOS/80 MICROLITROS SOLUCION INYECTABLE EN PLUMA PRECARGADA | LIVOGIVA 20 MICROGRAMOS/80 MICROLITROS SOLUCION INYECTABLE EN PLUMA PRECARGADA, 1 pluma percargada de 2,7 ml | 20 microgramos/dosis | 66 | 28 | 45 | 1 pluma percargada de 2,7 ml | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/1201462001/1201462001_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1201462001/1201462001_p.pdf | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29320 | THERAMEX IRELAND LIMITED | 2020-10-20 | 1 | 1 | 1 | 2020-10-21 | 2020-10-20 | 1 | 2021-03-10 | View Edit Delete |
Page 108 of 1035, showing 20 records out of 20689 total, starting on record 2141, ending on 2160